ClinicalTrials.gg

Program

Glycopyrrolate

Also written as “NVA237”, “BGF MDI 320/14.4/9.6 μg” and “GFF MDI (PT003)”.

Its studies are mostly in Pulmonary Disease, Chronic Obstructive · Asthma · Hyperhidrosis · Renal Insufficiency, led by 7 companies.

Furthest: phase 4, since Aug 9, 201352 company-led studies, 1 open or runningNext primary completion: Jul 30, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartis291 open or runningphase 4since Aug 9, 2013Jul 13, 2007Jul 30, 2027phase 2 · NCT05222529
Chiesi Farmaceutici150 open or runningphase 3since Aug 5, 2013Aug 5, 2010none ahead
Sumitomo Pharma30 open or runningphase 2since Oct 26, 2016Jul 24, 2015none ahead
Journey Medical20 open or runningphase 2since Dec 16, 2013Dec 16, 2013none ahead
Dr. August Wolff GmbH & Co. KG Arzneimittel10 open or runningphase 2since Apr 27, 2023Apr 27, 2023none ahead
NIOX Group10 open or runningphase 2since Oct 4, 2012Oct 4, 2012none ahead
sosei10 open or runningphase 2since Oct 19, 2005Oct 19, 2005none ahead

Also a collaborator on its studies: parexel, iqvia-pty-ltd, premier-inc, ciscrp and eresearchtechnology.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 37 studies since Oct 19, 2005.

  1. Jul 2, 2014Phase 2 study in Pulmonary Disease, Chronic ObstructiveChiesi Farmaceutici · NCT02189577 · 100 enrolled · Bulgaria, Germany, Poland and more
  2. Nov 14, 2014Phase 2 study in AsthmaChiesi Farmaceutici · NCT02296411 · 98 enrolled · Bulgaria, Germany, Italy and more
  3. Feb 19, 2015Phase 4 study in Pulmonary Disease, Chronic ObstructiveNovartis · NCT02371629 · 776 enrolled · Belgium, Bulgaria, Finland and more
  4. Jul 24, 2015Sumitomo Pharma's first study: phase 1 study in Pulmonary Disease, Chronic ObstructiveNew to Sumitomo PharmaSumitomo Pharma · NCT02512302 · 30 enrolled · United Kingdom
  5. Oct 26, 20162 phase 2 studies in Pulmonary Disease, Chronic ObstructiveSumitomo Pharma · NCT02951312, NCT02948582
  6. Nov 15, 2016Phase 1 study in Pulmonary Disease, Chronic ObstructiveChiesi Farmaceutici · NCT02975843 · 28 enrolled
  7. Mar 8, 2017Phase 2 study in Pulmonary Disease, Chronic ObstructiveChiesi Farmaceutici · NCT03084796 · 733 enrolled · United States
  8. Apr 24, 2017Phase 3 study in AsthmaNovartis · NCT03137784 · 148 enrolled · United States, Belgium, Germany and more
  9. Aug 23, 2017Phase 3 study in Pulmonary Disease, Chronic ObstructiveChiesi Farmaceutici · NCT03268226 · 20 enrolled · Belgium, Hungary
  10. Mar 23, 2020Phase 3 study in Pulmonary Disease, Chronic ObstructiveChiesi Farmaceutici · NCT04320342 · 3,406 enrolled · United States, Argentina, Bulgaria and more
  11. May 3, 2021Phase 3 study in Pulmonary Disease, Chronic ObstructiveChiesi Farmaceutici · NCT04876677 · 25 enrolled · Belgium, Hungary
  12. Jan 10, 2022Phase 2 study in AsthmaNovartis · NCT05222529 · 42 planned · Bulgaria, Colombia, Guatemala and more
  13. Mar 28, 2023Phase 1 study in AsthmaChiesi Farmaceutici · NCT05830071 · 95 enrolled · United States
  14. Apr 27, 2023Dr. August Wolff GmbH & Co. KG Arzneimittel's first study: phase 2 study in HyperhidrosisNew to Dr. August Wolff GmbH & Co. KG ArzneimittelDr. August Wolff GmbH & Co. KG Arzneimittel · NCT05863104 · 44 enrolled · Germany

Ahead

  1. Jul 30, 2027Primary completion: phase 2 study in AsthmaNovartis · NCT05222529

TargetBeta

“Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M1 antagonist; Muscarinic acetylcholine receptor inhibitor”ChEMBL 37, by rule

Studies

All 52 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT05863104Hyperhidrosis · Germany2CompletedDr. August Wolff GmbH & Co. KG ArzneimittelMar 6, 202444
NCT05830071Asthma · United States1CompletedChiesi FarmaceuticiOct 13, 202395
NCT05222529Asthma · Bulgaria, Colombia, Guatemala and more2RecruitingNovartisJul 30, 202742
NCT04876677Pulmonary Disease, Chronic Obstructive · Belgium, Hungary3CompletedChiesi FarmaceuticiJan 3, 202225
NCT04320342Pulmonary Disease, Chronic Obstructive · United States, Argentina, Bulgaria and more3CompletedChiesi FarmaceuticiJan 12, 20263,406
NCT03268226Pulmonary Disease, Chronic Obstructive · Belgium, Hungary3CompletedChiesi FarmaceuticiJan 30, 201920
NCT03137784Asthma · United States, Belgium, Germany and more3CompletedNovartisDec 29, 2017148
NCT03084796Pulmonary Disease, Chronic Obstructive · United States2CompletedChiesi FarmaceuticiMay 23, 2018733
NCT02975843Pulmonary Disease, Chronic Obstructive1CompletedChiesi FarmaceuticiMar 21, 201728
NCT02951312Pulmonary Disease, Chronic Obstructive2CompletedSumitomo PharmaJul 200912
NCT02948582Pulmonary Disease, Chronic Obstructive2CompletedSumitomo PharmaNov 201042
NCT02512302Pulmonary Disease, Chronic Obstructive · United Kingdom1CompletedSumitomo PharmaApr 201630
NCT02371629Pulmonary Disease, Chronic Obstructive · Belgium, Bulgaria, Finland and more4CompletedNovartisNov 16, 2016776
NCT02296411Asthma · Bulgaria, Germany, Italy and more2CompletedChiesi FarmaceuticiAug 13, 201598
NCT02189577Pulmonary Disease, Chronic Obstructive · Bulgaria, Germany, Poland and more2CompletedChiesi FarmaceuticiFeb 2015100
NCT02202616Pulmonary Disease, Chronic Obstructive · Canada4CompletedNovartisApr 5, 2017401
NCT02129660Hyperhidrosis · United States, Canada2CompletedJourney MedicalJan 2015105
NCT02127697Asthma3WithdrawnNovartisMay 20170
NCT02119234Pulmonary Disease, Chronic Obstructive · Poland1CompletedChiesi FarmaceuticiFeb 201536
NCT02040597Pulmonary Disease, Chronic Obstructive · Poland1CompletedChiesi FarmaceuticiApr 201542
NCT02016885Hyperhidrosis · United States2CompletedJourney MedicalSep 2014198
NCT01985334Pulmonary Disease, Chronic Obstructive · Austria, Belgium, Czechia and more4CompletedNovartisApr 29, 20164,389
NCT01959516Pulmonary Disease, Chronic Obstructive · Germany, Italy, Spain and more4CompletedNovartisOct 2014124
NCT01922271Pulmonary Disease, Chronic Obstructive · Germany4CompletedNovartisJan 2014152
NCT01917331Pulmonary Disease, Chronic Obstructive · Hungary3CompletedChiesi FarmaceuticiJan 14, 20161,368
NCT01837927Pulmonary Disease, Chronic Obstructive3WithdrawnNovartisApr 20160
NCT01757015Pulmonary Disease, Chronic Obstructive3WithdrawnNovartisApr 20140
NCT01715298Pulmonary Disease, Chronic Obstructive · United States3CompletedNovartisDec 2013432
NCT01709864Pulmonary Disease, Chronic Obstructive · United States3CompletedNovartisOct 2013440
NCT01703624Pulmonary Disease, Chronic Obstructive · United Kingdom2CompletedNIOX GroupAug 201337
NCT01699685Pulmonary Disease, Chronic Obstructive · Switzerland3CompletedNovartisJun 201479
NCT01697696Pulmonary Disease, Chronic Obstructive · United States3CompletedNovartisNov 2014511
NCT01613690Renal Insufficiency · Russian Federation1CompletedNovartisNov 201048
NCT01604278Pulmonary Disease, Chronic Obstructive · Belgium, Bulgaria, Greece and more3CompletedNovartisJan 2013449
NCT01566604Pulmonary Disease, Chronic Obstructive · China, India, Korea, Republic of and more3CompletedNovartisJun 2013460
NCT01613326Pulmonary Disease, Chronic Obstructive · Canada, Croatia, Czech Republic and more3CompletedNovartisJan 2013657
NCT01513460Pulmonary Disease, Chronic Obstructive · Australia, New Zealand3CompletedNovartisDec 2013773
NCT01476813Pulmonary Disease, Chronic Obstructive · United Kingdom2CompletedChiesi FarmaceuticiSep 2012281
NCT01398111Pulmonary Disease, Chronic Obstructive · Belgium1CompletedChiesi FarmaceuticiAug 201144
NCT01176903Pulmonary Disease, Chronic Obstructive · United Kingdom2CompletedChiesi FarmaceuticiNov 201065
NCT01176851Healthy · United Kingdom1CompletedChiesi FarmaceuticiOct 201020
NCT01154127Pulmonary Disease, Chronic Obstructive · United States, Germany, Italy and more3CompletedNovartisFeb 2011108
NCT01119950Pulmonary Disease, Chronic Obstructive · United States, Belgium, Germany and more2CompletedNovartisDec 2010388
NCT01119937Pulmonary Disease, Chronic Obstructive · Japan3CompletedNovartisNov 2011211
NCT01005901Pulmonary Disease, Chronic Obstructive · United States, Australia, Canada and more3CompletedNovartisDec 20101,324
NCT00929110Pulmonary Disease, Chronic Obstructive · United States, Argentina, Canada and more3CompletedNovartisApr 20111,066
NCT00856193Pulmonary Disease, Chronic Obstructive · United States, Germany2CompletedNovartisMay 200933
NCT00558285Pulmonary Disease, Chronic Obstructive · Australia, Belgium, Canada and more2CompletedNovartisJul 2008257
NCT00545311Pulmonary Disease, Chronic Obstructive · Denmark, Germany1CompletedNovartis40
NCT00510510Pulmonary Disease, Chronic Obstructive · United States, France, Germany and more2CompletedNovartisJan 2008281
NCT00501852Pulmonary Disease, Chronic Obstructive · Belgium, France, Japan2CompletedNovartisDec 200783
NCT00242333Pulmonary Disease, Chronic Obstructive · Bulgaria, Hungary, Poland and more2Completedsosei300

How it is read

Names in the registry

  • “NVA237”, 20 entries
  • “Glycopyrrolate”, 8 entries
  • “BGF MDI 320/14.4/9.6 μg”, 6 entries
  • “GFF MDI (PT003)”, 6 entries
  • “Indacaterol maleate and glycopyrronium bromide”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.